Portal de Periódicos da CAPES

Revisão Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?

2024; Multidisciplinary Digital Publishing Institute; Volume: 16; Issue: 11 Linguagem: Inglês

10.3390/v16111710

1999-4915

Giovana Angelice, Pedro Henrique da Conceição Roque, Guido Valente, Krishna Galvão, Lívia Melo Villar, Vinicius M. Mello, Francisco Campello do Amaral Mello, Bárbara V. Lago,

Animal Virus Infections Studies

Despite an existing safe and effective vaccine for hepatitis B virus (HBV), it is still a major public health concern. Nowadays, several drugs are used to treat chronic hepatitis B; however, full healing remains controversial. The viral covalently closed circular DNA (cccDNA) formed by HBV forms a major challenge in its treatment, as does the ability of HBV to integrate itself into the host genome, which enables infection reactivation. Interfering RNA (RNAi) is a gene-silencing post-transcriptional mechanism which forms as a promising alternative to treat chronic hepatitis B. The aim of the present review is to assess the evolution of hepatitis B treatment approaches based on using RNA interference.